Bayer Will Appeal India Compulsory Licence On Its Cancer Drug 05/03/2013 by Intellectual Property Watch 7 Comments German pharmaceutical manufacturer Bayer has announced it will appeal yesterday’s ruling in India that upheld a compulsory licence on one of its drugs.
India’s First Compulsory Licence Upheld, But Legal Fights Likely To Continue 04/03/2013 by Patralekha Chatterjee for Intellectual Property Watch 6 Comments New Delhi – India’s Intellectual Property Appellate Board (IPAB) today upheld the country’s first compulsory licence on a pharmaceutical product. The much-awaited verdict by Justice (Ms) Prabha Sridevan upholds the compulsory licence issued to Hyderabad-based Natco Pharma Ltd, an Indian generic drug manufacturer, which sells a much cheaper version of German pharmaceutical company Bayer AG’s kidney and liver cancer drug Nexavar in the market.
Should Industry Support LDCs’ Request For Unlimited Time To Implement The TRIPS Agreement? Absolutely 04/03/2013 by Intellectual Property Watch 3 Comments Nick Ashton-Hart writes: Some of you may have noticed that the ICT sector trade association that I represent in Geneva, the Computer and Communication Industry Association (CCIA), has endorsed a bid by the world’s Least Developed Countries (LDC’s) to remove any specific deadline for full compliance with the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement.
Russia Establishes Specialised Court For Intellectual Property Rights 01/03/2013 by Daria Kim for Intellectual Property Watch 1 Comment As of 1 February 2013, a specialised court for intellectual property rights (the IPR Court) is instituted within the system of commercial (‘arbitrazh’) courts of the Russian Federation.
Speakers Outline Ideas For Africa To Find Appropriate IP Policies 01/03/2013 by Linda Daniels for Intellectual Property Watch 6 Comments Johannesburg, South Africa – Africa is still held captive by colonial borders and has failed to collectively leverage benefit-sharing agreements that result from multinationals’commercial pursuit of indigenous knowledge, said speakers at the Africa IP conference this week.
Global Health Giants, Trade Deals, And IP Play Central Role In 2013 Public Health Policy 28/02/2013 by Rachel Marusak Hermann, Intellectual Property Watch Leave a Comment The role of intellectual property in a wide range of public health challenges – access to medicines, vaccine prices, procurement strategies, and research for diseases of the poor – is a focal point in 2013 cutting across national, regional, and international policymaking.
With Lively Start, African IP Conference Addresses Medicines Access, GIs 27/02/2013 by Linda Daniels for Intellectual Property Watch Leave a Comment Johannesburg, South Africa — The start of the Africa IP conference was the scene of a surprise protest action by Treatment Action Campaign health activists who ambushed the stage as South African Trade and Industry Minister Rob Davies was about to welcome delegates to the three-day conference.
Report Finds Stronger Regulation Spurs Chemical Innovation 26/02/2013 by Intellectual Property Watch 2 Comments New research shows that more rigid laws regulating hazardous chemicals encourage innovation in both large and small companies, according to a report published by the Center for International Environmental Law (CIEL).
Web-Based IP Assessment Tool Gets Update From USPTO 25/02/2013 by Intellectual Property Watch Leave a Comment The United States Patent and Trademark Office (USPTO) today released an updated version of their web-based intellectual property assessment tool, which aims to make small and medium-sized enterprises (SMEs) more aware of their IP assests.
European Commission Seeks Comments On Licensing For Tech Transfer 21/02/2013 by Intellectual Property Watch Leave a Comment The European Commission announced today that it is inviting comments on a proposal for new competition rules for the assessment of technology transfer agreements. Under the rules, a licensor permits a licensee to exploit patents, know-how or software for the production of goods and services, it said.